
Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) – Analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Tempest Therapeutics in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.49) for the year, up from their previous estimate of ($0.83). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.49) EPS and FY2028 earnings at ($0.46) EPS.
Several other equities analysts have also recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempest Therapeutics in a report on Friday, October 9th. Wall Street Zen raised Tempest Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.
Tempest Therapeutics Stock Performance
Shares of Tempest Therapeutics stock opened at $0.31 on Wednesday. Tempest Therapeutics has a 1 year low of $0.29 and a 1 year high of $4.75. The business has a 50-day moving average of $0.64 and a two-hundred day moving average of $1.34.
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.11.
Institutional Trading of Tempest Therapeutics
An institutional investor recently bought a new position in Tempest Therapeutics stock. Squarepoint Ops LLC bought a new position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned about 0.19% of Tempest Therapeutics at the end of the most recent quarter. 22.52% of the stock is currently owned by hedge funds and other institutional investors.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company focused on developing treatments for cancer. The company’s research centers on small-molecule medicines designed to affect biological pathways involved in tumor growth and the immune response. Its lead candidate, TPST-1120, is an oral inhibitor of PPARα that has been studied for advanced liver cancer, including in combination with other cancer therapies. Tempest has also worked on additional drug candidates targeting immune-related pathways.
Recommended Stories
- Five stocks we like better than Tempest Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
